These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 22348692)
21. Importance of early recognition of heterozygous familial hypercholesterolaemia. Ryan A; Byrne CD Curr Opin Lipidol; 2015 Aug; 26(4):298-303. PubMed ID: 26103611 [TBL] [Abstract][Full Text] [Related]
22. Spectrum of LDLR gene mutations, including a novel mutation causing familial hypercholesterolaemia, in North-western Greece. Diakou M; Miltiadous G; Xenophontos SL; Manoli P; Cariolou MA; Elisaf M Eur J Intern Med; 2011 Oct; 22(5):e55-9. PubMed ID: 21925044 [TBL] [Abstract][Full Text] [Related]
23. Beyond cascade screening: detection of familial hypercholesterolaemia at childhood immunization and other strategies. Martin AC; Bell DA; Brett T; Watts GF Curr Opin Lipidol; 2017 Aug; 28(4):321-327. PubMed ID: 28426524 [TBL] [Abstract][Full Text] [Related]
24. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Umans-Eckenhausen MA; Defesche JC; Sijbrands EJ; Scheerder RL; Kastelein JJ Lancet; 2001 Jan; 357(9251):165-8. PubMed ID: 11213091 [TBL] [Abstract][Full Text] [Related]
25. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. Pećin I; Hartgers ML; Hovingh GK; Dent R; Reiner Ž Eur J Prev Cardiol; 2017 Sep; 24(13):1383-1401. PubMed ID: 28644091 [TBL] [Abstract][Full Text] [Related]
26. Are patients with familial hypercholesterolaemia well managed in lipid clinics? An audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing project. Hadfield SG; Horara S; Starr BJ; Yazdgerdi S; Bhatnagar D; Cramb R; Egan S; Everdell R; Ferns G; Jones A; Marenah CB; Marples J; Prinsloo P; Sneyd A; Stewart MF; Sandle L; Wang T; Watson MS; Humphries SE Ann Clin Biochem; 2008 Mar; 45(Pt 2):199-205. PubMed ID: 18325186 [TBL] [Abstract][Full Text] [Related]
27. Individuals' experiences of, and responses to, a negative genetic test result for familial hypercholesterolaemia. Hilgart J; Mercer J; Thirlaway K J Health Psychol; 2013 Mar; 18(3):339-49. PubMed ID: 22517949 [TBL] [Abstract][Full Text] [Related]
28. Documenting family history in children with hypercholesterolaemia: A lost opportunity. Sorubarajan T; Lewis BD; Burnett JR; Martin AC J Paediatr Child Health; 2017 May; 53(5):470-473. PubMed ID: 28045210 [TBL] [Abstract][Full Text] [Related]
29. Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia. Silva PR; Jannes CE; Marsiglia JD; Krieger JE; Santos RD; Pereira AC Atherosclerosis; 2016 Jul; 250():144-50. PubMed ID: 27214396 [TBL] [Abstract][Full Text] [Related]
30. Being at risk for cardiovascular disease: perceptions and preventive behavior in people with and without a known genetic predisposition. Claassen L; Henneman L; van der Weijden T; Marteau TM; Timmermans DR Psychol Health Med; 2012; 17(5):511-21. PubMed ID: 22360457 [TBL] [Abstract][Full Text] [Related]
31. No certain predictors for mutation status in a Danish cohort with familial hypercholesterolemia: a descriptive study. Nybo M; Brusgaard K; Hansen AB Clin Biochem; 2007 Dec; 40(18):1347-52. PubMed ID: 17961529 [TBL] [Abstract][Full Text] [Related]
32. Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992-2013. Mundal L; Igland J; Ose L; Holven KB; Veierød MB; Leren TP; Retterstøl K Eur J Prev Cardiol; 2017 Jan; 24(2):137-144. PubMed ID: 27794106 [TBL] [Abstract][Full Text] [Related]
33. Molecular testing for familial hypercholesterolaemia-associated mutations in a UK-based cohort: development of an NGS-based method and comparison with multiplex polymerase chain reaction and oligonucleotide arrays. Reiman A; Pandey S; Lloyd KL; Dyer N; Khan M; Crockard M; Latten MJ; Watson TL; Cree IA; Grammatopoulos DK Ann Clin Biochem; 2016 Nov; 53(6):654-662. PubMed ID: 26748104 [TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Wonderling D; Umans-Eckenhausen MA; Marks D; Defesche JC; Kastelein JJ; Thorogood M Semin Vasc Med; 2004 Feb; 4(1):97-104. PubMed ID: 15199439 [TBL] [Abstract][Full Text] [Related]
37. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. Humphries SE; Cranston T; Allen M; Middleton-Price H; Fernandez MC; Senior V; Hawe E; Iversen A; Wray R; Crook MA; Wierzbicki AS J Mol Med (Berl); 2006 Mar; 84(3):203-14. PubMed ID: 16389549 [TBL] [Abstract][Full Text] [Related]
38. The genetics and screening of familial hypercholesterolaemia. Henderson R; O'Kane M; McGilligan V; Watterson S J Biomed Sci; 2016 Apr; 23():39. PubMed ID: 27084339 [TBL] [Abstract][Full Text] [Related]
39. A new model of care for familial hypercholesterolaemia from Western Australia: closing a major gap in preventive cardiology. Watts GF; van Bockxmeer FM; Bates T; Burnett JR; Juniper A; O'Leary P Heart Lung Circ; 2010 Jul; 19(7):419-22. PubMed ID: 20363671 [TBL] [Abstract][Full Text] [Related]
40. [Management of familial heterozygous hypercholesterolaemia. Position paper of the Polish Lipid Expert Forum]. Rynkiewicz A; Cybulska B; Banach M; Filipiak KJ; Guzik T; Idzior Waluś B; Imiela J; Jankowski P; Kłosiewicz Latoszek L; Limon J; Myśliwiec M; Opolski G; Steciwko A; Stępińska J; Zdrojewski T; Kardiol Pol; 2013; 71(1):107-11. PubMed ID: 23348551 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]